A Phase 3, randomized, double-blind, double-dummy, multicenter, multinational study to assess the efficacy and safety of orally administered tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenously (IV) administered imipenem-cilastatin in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)
CompletedCTIS2023-503785-22-00
Spero Therapeutics Inc.complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)
Start: 2024-03-25End: 2025-05-28Target: 1454Updated: 2025-06-09